Strategic aspirations for 2025

Our strategic aspirations for 2025 cover four areas:

Purpose and sustainability

  • Being respected for adding value to society
  • Progress towards zero environmental impact
  • Ensure distinct core capabilities and evolve culture

Innovation and therapeutics

  • Further raise the innovation-bar for diabetes treatment
  • Develop a leading portfolio of superior treatment solutions for obesity
  • Strengthen and progress the Biopharm pipeline
  • Establish presence in Other serious chronic diseases focusing on Cardiovascular disease (CVD); Non-alcoholic steatohepatitis (NASH) and Chronic kidney disease (CKD)

Commercial execution

  • Strengthen Diabetes leadership - aim at global value market share of more than 1/3
  • Strengthen Obesity leadership and double current sales (based on reported sales in 2019)
  • Secure a sustained growth outlook for Biopharm


  • Deliver solid sales and operating profit growth:
    • Deliver 6-10% sales growth in International Operations
    • Transform 70% of sales in the USA (from 2015 to 2022)
  • Drive operational efficiencies across the value chain to enable investments in future growth assets
  • Deliver free cash flow to enable attractive capital allocation to shareholders

Please note

Our strategic aspirations are not a projection of our financial outlook or expected growth.

Unless otherwise specified growth rates are at constant exchange rates.


Highlights for the first six months of 2020


Adding value to society

  • Launch of new social responsibility strategy to defeat diabetes
  • Participation in antimicrobial resistance initiative
  • Expansion of US affordability offerings
  • Societal contributions during COVID-19 pandemic

Green power

Sourcing of green power at all US operations and 100% renewable power across all production sites

CO2 emissions

39% reduction in CO2 emissions compared to the first half of 2019 due to use of renewable energy and lower travel activities



  • Insulin icodec phase 2 trial successfully completed
  • Rybelsus® approved in the EU, the UK and Japan


  • Successful completion of obesity trials:
  • Semaglutide obesity phase 3 programme
  • AM833 monotherapy phase 2 trial
  • AM833 in combination with semaglutide phase 1 trial

Other serious chronic disease

  • Agreement to acquire of Corvidia Therapeutics
  • Positive phase 2 data for semaglutide in Non-alcoholic steatohepatitis (NASH)


Diabetes sales increased by 7%

  • Value market share leadership expanded by 0.8%-points to 29.0%
  • Sales of GLP-1 increased by 28% driven by continued performance of Ozempic®

Obesity sales increased by 9% to DKK 2.9 billion

Biopharm sales increased by 6%

  • Driven by International Operations and North America Operations


Sales increased by 7%, to DKK 63.9 billion

  • 12% and 1% growth in Interntional Operations and North America Operations, respectively
  • In the US, 46% of sales transformed to products launched since 2015

Operating profit increased by 8% to DKK 30.1 billion

  • Productivity improvement and improved admin-to-sales ratio

Interim dividend

  • An interim dividend of DKK 3.25 for each Novo Nordisk A and B share of DKK 0.20, which was paid in August 2020
Contact investor relations

If you have any questions to our strategic aspirations, you are welcome to contact Novo Nordisk Investor Relations

Related content

Explore more

Huw Bevan from UK has type 2 diabetes

100% renewable power target for suppliers

We have set ourselves an ambitious target of ensuring that all of our direct suppliers supply our business using 100% renewable power by 2030.

ช่าง ภาพ

Preventing chronic diseases

We need a future where fewer people are living with type 2 diabetes and obesity. We are working with global partners to make it a reality.